Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Results of KEYNOTE-054; melanoma patients treated with pembrolizumab.

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 177

Prof Alex Eggermont - Paris-Sud University, Paris, France

Prof Eggermont presents results at AACR 2018 from KEYNOTE-054, assessing disease recurrence rates in melanoma patients treated with pembrolizumab.

For more on this research, watch his interview with ecancer here.

Related videos

follow us

Siyemi immunocology e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation